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INTRODUCTION
Primary intraocular lymphoma is classified together with 
primary central nervous system lymphoma,1-4 and must be 
differentiated from secondary intraocular lymphoma, which 
is the infiltration of lymphoma developing outside of the cen-
tral nervous system.5-7   Lymphoma in the eye manifests as 
vitreous opacity with or without infiltrative lesions in the sen-
sory retina, subretinal pigment epithelium, or optic nerve.1,8 
The diagnosis of lymphoma requires differential diagnosis 
from intraocular inflammatory diseases, namely, uveitis, 
which exhibit similar symptoms.9   The pathological diagno-
sis is carried out by immunostaining of paraffin sections of 
cell blocks obtained at vitrectomy for vitreous opacity.2,9
Primary intraocular lymphoma frequently develops into 
central nervous system lymphoma simultaneously or subse-
quently at a different time point.   Primary central nervous 
system lymphoma may be followed later by the diagnosis of 
intraocular lymphoma.   The interval between the development 
of intraocular lymphoma and central nervous system lym-
phoma varies over a long period of time.
We previously reported 11 consecutive patients with pri-
mary intraocular lymphoma.2   In this study, we included 11 
additional patients with primary intraocular lymphoma and 
assessed whether there are primary intraocular lymphomas 
that do not develop into central nervous system lymphoma 
during long-term follow-up.   We also reviewed the results of 
CD5 immunostaining of large cells in vitrectomy cell blocks 
because CD5-positive diffuse large B-cell lymphoma is 
known for central nervous system infiltration.10
METHODS
This retrospective study included 22 consecutive patients 
with primary intraocular lymphoma who were diagnosed and 
followed between January 2005 and April 2019 (Table 1). 
The initial 11 patients were previously reported,2 and their 
outcomes after May 2008 were further examined.   The study 
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brain lesion Treatment and outcome
1 68/Male 4 yr 2 mo Right eye No Yes Yes n.d. Yes simultaneous Chemotherapy
Died of brain lymphoma
Left eye No Yes Yes n.d.
2 72/Male 2 yr 4 mo Right eye No Yes Yes n.d. Yes 1 mo later Chemotherapy
Died of brain lymphoma
Left eye Yes Yes Yes n.d.
3 68/Male 7 mo Right eye No Yes Yes n.d. No No additional treatment
Renal dialysis after nephritis for 
past 4 yr 
Died of renal failure
Left eye No Yes Yes n.d.




Alive at final follow-up, lost 
thereafter
Left eye No No No
5 72/Female 5 yr 8 mo Right eye No Yes Yes n.d. No No additional treatment
Left sphenoid ridge to orbital 
meningioma 26 yr previously
Died of other causes
Left eye Unknown
6 69/Female 5 yr 8 mo Right eye No Yes Yes n.d. Yes 1 yr 10 mo 
previously
Chemotherapy
Died of brain lymphoma
Left eye No Yes Yes n.d.
7 76/Male 2 yr 4 mo Right eye Yes Yes Yes n.d. Yes 10 mo 
previously
Chemotherapy
Brain radiation (40 Gy)
Alive at final follow-up, lost 
thereafter
Left eye Yes Yes Yes n.d.
8 70/Female 2 yr 1 mo Right eye No Yes Yes Negative Yes 1 mo later Chemotherapy
Died of brain lymphoma
Left eye No No No
9 74/Female 1 yr 7 mo Right eye No Yes Yes n.d. Yes 11 mo later Chemotherapy
Died of brain lymphoma
Left eye Yes Yes Yes n.d.
10 79/Female 8 mo Right eye Yes Yes Yes n.d. No Right eye radiation (40 Gy)
Died of pancytopenia
Left eye No No No
11 82/Female 11 yr Right eye No No No No No additional treatment
Alive at last visit
Left eye No Yes Yes n.d.
12 84/Female 10 mo Right eye No Yes Yes Positive Yes 3 mo later Chemotherapy
Died of brain lymphoma
Left eye No Yes Yes Positive
13 42/Female 7 yr 2 mo Right eye No Yes Yes n.d. Yes 5 yr later Vitreal MTX in both eyes at other 
hospital
Prophylactic systemic MTX & 
Ara-C
AutoPBSCT 5 yr later
Alive at last visit
Left eye No Yes Yes n.d.
14 74/Male 9 mo Right eye No No No Yes 1 mo later Chemotherapy
Died of brain lymphoma
Left eye Yes Yes Yes Negative
15 64/Male 6 yr 5 mo Right eye No Yes Yes n.d. Yes 1.5 yr 
previously
Chemotherapy
AutoPBSCT 1.5 yr previously
Brain & both eyes radiation 2 yr 
later
Alive at last visit
Left eye No Yes Yes n.d.
16 73/Female 6 yr 4 mo Right eye No No No n.d. Yes 4.5 yr later Chemotherapy 4.5 yr later
Alive at last visit
Left eye No Yes Yes n.d.
Table 1. Clinical features of the 22 consecutive patients with primary intraocular lymphoma 
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was performed according to the Declaration of Helsinki and 
was approved as a retrospective study by the ethics commit-
tee of Okayama University Graduate School of Medicine, 
Dentistry, and Pharmaceutical Sciences and Okayama 
University Hospital.   All 22 patients underwent vitreous sur-
gery (vitrectomy) for vitreous opacity by a single surgeon 
(TM) at Okayama University Hospital, and were diagnosed 
with large B-cell lymphoma by immunostaining of paraffin 
sections of vitrectomy cell  blocks at  the pathology 
department.2,9
Vitrectomy fluid in two or more 50-mL disposable tubes 
was mixed with one-tenth the volume of 4% paraformalde-
hyde and centrifuged for 20 minutes at 3000 revolutions per 
minute (rpm) at room temperature.   The pellet in each tube 
was suspended in a small volume of 4% paraformaldehyde, 
combined in one 15-mL disposable tube, and centrifuged for 
15 minutes at 3000 rpm at room temperature.2,9   The final 
pellet was embedded in paraffin, and sections were cut and 
stained by hematoxylin-eosin.   Immunohistochemical stain-
ing was based on the protocol recommended for the Bond 
Polymer Refine Detection Kit in the system of Bond-III Fully 
Automated IHC and ISH Stainer (Leica Biosystems, Welzlar, 
Germany).   Primary antibodies used were: mouse monoclo-
nal antibodies against CD3 (LN10 clone, 1:200 dilution), 
CD5 (4C7 clone, 1:100 dilution), CD20 (L26 clone, 1:150 
dilution), and Ki67 (MM1 clone, 1:200 dilution, Leica 
Biosystems Novocastra).   The pathological diagnosis was based 
on large cells with anomalous nuclei on hematoxylin-eosin 
staining being positive for CD20 and Ki67, but negative for 
CD3.   The Ki67 labeling index was set at 50% or higher.
RESULTS
The 22 consecutive patients were 14 women and 8 men, 
with the age at initial visit for eye examinations ranging from 
42 to 84 years (median, 71 years).   The follow-up period 
ranged from 5 months to 11 years (median, 2 years and 10 
months).   Both eyes were affected by the intraocular lym-
phoma in 12 patients, whereas only the right eye or left eye 
was involved in 6 patients and 4 patients, respectively. 
Regarding treatments, systemic chemotherapy was performed 
for 8 patients, whole brain radiation after systemic chemo-
therapy for 4 patients, autologous peripheral blood stem cell 
transplantation after chemotherapy for 3 patients, whole brain 
radiation for one patient, chemotherapy with eye radiation for 
2 patients, eye radiation for one patient, and no treatment for 
3 patients (Table 1).
Of the 22 patients with primary intraocular lymphoma 
(Table 1), 17 developed central nervous system lymphoma: 3 
patients developed intraocular and central nervous system 
lymphoma simultaneously, 9 patients developed central ner-
vous system lymphoma 1 month to 5 years (median, 3 
months) after the development of intraocular lymphoma, and 
5 patients developed central nervous system lymphoma pre-
ceding the diagnosis of intraocular lymphoma by 3 months to 
9 years and 8 months (median, 1 years and 6 months).
17 81/Female 5 mo Right eye No No No n.d. Yes simultaneous Brain radiation
Died of brain lymphoma
Left eye No Yes Yes n.d.
18 68/Female 2 yr 10 mo Right eye No Yes Yes Positive Yes 5 mo later Chemotherapy 5 mo later
Brain radiation 2 yr later
Died of brain lymphomaLeft eye No Yes Yes Positive
19 70/Male 1 yr 3 mo Right eye No Yes Yes Negative Yes simultaneous Chemotherapy, Brain radiation
Died of brain lymphoma
Left eye No No No
20 63/Female 4 yr 8 mo Right eye No Yes Yes Negative Yes 2 mo later Chemotherapy, autoPBSCT
2nd autoPBSCT 3 yr later
Died of brain lymphomaLeft eye No Yes Yes Negative
21 76/Female 3 yr Right eye No Yes Yes Negative No Chemotherapy
Both eyes radiation 2 yr 5 mo 
later
Left eye lesion and vitrectomy 2 
yr 4 mo later
Alive at last visit
Left eye No Yes Yes Negative
22 69/Male 3 yr Right eye No Yes Yes Positive Yes 9 yr and 8 
mo 
previously
Systemic MTX and brain radia-
tion previously at other hospital
Right eye recurrence at initial 
visit
Right eye radiation and systemic 
MTX 1 yr later
Alive at last visit
Left eye No No No
*Age (years) at initial visit for eye examination. #Onset of brain lesion relative to the onset of eye manifestations. “Later” or “previously” rel-
ative to initial visit to ophthalmology department. Chemotherapy indicates systemic chemotherapy (usually R-CHOP with or without metho-
trexate) and brain radiation indicates whole-brain radiation. Systemic MTX indicates high-dose MTX. “Last visit” was in April 2019. 
Abbreviations are: n.d., not described; yr, years; mo, months, MTX, methotrexate; Ara-C, cytarabine; autoPBSCT, autologous peripheral 
blood stem cell transplantation.
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In contrast, the other 5 patients did not develop central 
nervous system lymphoma during the follow-up period.   Of 
these 5 patients, 3 had an insufficient follow-up period after 
the diagnosis of primary intraocular lymphoma.   One patient 
(Case 3) who was on renal dialysis for 4 years before diagnosis 
died of renal failure approximately half a year after the diag-
nosis of primary intraocular lymphoma, and the other patient 
(Case 10) died approximately half a year after right eye radi-
ation for the recurrent intraocular lesion.   These 2 patients 
did not undergo systemic chemotherapy.   The third patient 
(Case 21, Fig. 1) developed primary intraocular lymphoma 
first in the right eye and underwent prophylactic systemic 
chemotherapy even though magnetic resonance imaging 
demonstrated no brain lesion.   She developed intraocular 
lymphoma in the left eye approximately 2.5 years later, and 
underwent prophylactic radiotherapy for both eyes even 
though local recurrence was not observed in either eye.   She 
was followed further for half a year and was alive at the last 
Fig. 1. Case 21. Top, right eye. Bottom, left eye. A 76-year-old woman developed primary 
intraocular lymphoma in the right eye (top) and underwent prophylactic systemic chemother-
apy. She developed primary intraocular lymphoma in the left eye (bottom) 2.5 years later and 
then underwent radiation for both eyes. Large cells (A, G) in vitrectomy cell blocks are posi-
tive for CD20 (B, H) and Ki67 (F, L), but negative for CD3 (C, I), CD5 (D, J), and CD10 
(E, K). White bar = 50 μm.
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visit for this study.
The fourth patient (Case 5, Fig. 2, top) had been followed 
up for 5 years until death by other causes after the diagnosis 
of primary intraocular lymphoma.   The fifth patient (Case 
11, Fig. 2, bottom) had been followed up for 11 years after 
the diagnosis of primary intraocular lymphoma and was alive 
at the last visit for this study.   These 2 patients did not 
undergo additional local or systemic chemotherapy, or radia-
tion of the eye.
The results of CD5 immunostaining of vitrectomy speci-
mens in the pathology reports were found for 8 of the 22 con-
secutive patients with primary intraocular lymphoma: 3 
patients had CD5-positive large cells, whereas 5 had CD5-
negative large cells (Table 1).   Four patients had the vitreous 
of both eyes examined: 2 patients had CD5- positive large 
cells, whereas the other 2 had CD5-negative large cells in the 
Fig. 2. Top. Case 5. A 72-year-old woman was alive for 5 years after the diagnosis of primary 
intraocular lymphoma in the right eye and died of other causes. Large cells (A) in the vitrec-
tomy cell block are positive for CD20 (B) and Ki67 (D), but negative for CD3 (C). Bottom. 
Case 11. An 82-year-old woman was alive at the last visit for this study 11 years after the diag-
nosis of primary intraocular lymphoma in the left eye. Large cells (arrows in E) in the vitrec-
tomy cell block are positive for CD20 (F) and Ki67 (H), but negative for CD3 (G). CD3-
positive T cells are also present (G). White bar = 50 μm.
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vitreous of both eyes.   The 3 patients with CD5-positive 
large cells and 4 patients with CD5-negative large cells in the 
vitreous of one or both eyes developed central nervous sys-
tem lymphoma.   Only one patient (Case 21, Fig. 1) with 
CD5-negative large cells in the vitreous of both eyes did not 
develop central nervous system lymphoma during the short-
term follow-up of half a year until the last visit for this study.
DISCUSSION
Primary intraocular lymphoma naturally has a good prog-
nosis if it does not develop into central nervous system lym-
phoma.   The goals of this study were to find patients with 
primary intraocular lymphoma who did not develop central 
nervous system lymphoma during follow-up, and to examine 
whether CD5-positive large cells in vitrectomy specimens are 
a marker of central nervous system lymphoma.
CD5-positive diffuse large B-cell lymphoma was known 
to have a poor prognosis due to the higher incidence of cen-
tral nervous system infiltration.10   In contrast, large B-cells in 
primary intraocular lymphoma were found to be CD5-
negative by flow cytometry analysis of vitrectomy speci-
mens.11   To the best of our knowledge, there is only one case 
report describing CD5-positive abnormal cells in vitreous 
specimens by flow cytometry.12   In the present study, we 
revealed CD5-positive large cells and CD5-negative large 
cells by immunostaining in the sections of vitrectomy cell 
blocks from the series of patients with primary intraocular 
lymphoma.   However, CD5-positive or -negative large 
B-cells in vitrectomy specimens of primary intraocular lym-
phoma cannot be used as a marker of the development of 
central nervous system lymphoma.   No further evidence of 
the origin of lymphoma cells, such as myc expression or 
translocation, was available in the present study.
Most patients with central nervous system lymphoma 
died of the disease.   It should be noted that one young 
patient (Case 13) developed primary intraocular lymphoma 
in both eyes at the age of 42, and immediately underwent 
prophylactic systemic chemotherapy using methotrexate and 
cytarabine.   She also received intravitreal injection of metho-
trexate at another hospital before systemic chemotherapy. 
However, 5 years later, she developed a brain lesion and 
underwent autologous peripheral blood stem cell transplanta-
tion as a standard treatment option.13-15   She was well for the 
following 2 years until the last visit for this study.
As shown by the course of this patient (Case 13), there is 
no established standard treatment strategy for primary intra-
ocular lymphoma.   In addition, it remains controversial 
whether prophylactic treatment, systemic chemotherapy or 
radiotherapy to the eye or brain, can prevent future brain 
lesions, thereby improving the survival of patients with pri-
mary intraocular lymphoma.16-18   It also remains unknown 
whether intravitreal methotrexate injection after vitrectomy 
for primary intraocular lymphoma plays a role in preventing 
central nervous system lymphoma.18-20
At our hospital, intravitreal methotrexate injection is not 
performed for patients with primary intraocular lymphoma 
because it is not approved by health insurance in Japan.   In 
the present series of 22 patients, only 2 (Case 10 and Case 
22) developed local recurrence in the eye after vitrectomy 
and underwent whole eye radiation.   The other 20 patients 
did not exhibit local recurrence in the eye after vitrectomy 
alone.   It should be noted that 2 patients (Case 5 and Case 
11, Fig. 2) with primary intraocular lymphoma after vitrec-
tomy alone did not develop local recurrence in the eye or 
central nervous system lymphoma during long-term 
follow-up.
In conclusion, a small number of patients with primary 
intraocular lymphoma did not develop central nervous sys-
tem lymphoma after vitrectomy alone without additional 
local or systemic treatment.   At present, there is no marker 
available to predict whether a patient with primary intraocu-
lar  lymphoma wil l  develop central  nervous system 
lymphoma.
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